ABIGAIL OWUNNA, NP-C
Family Nurse Practitioner · AUSTIN, TX
Individual Active NPI 1922597699
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 599 | 212,692 | $14,077,851 | $3,576,036 | $2,844,763 |
| 2023 | 575 | 146,182 | $11,189,063 | $2,957,144 | $2,353,119 |
| 2022 | 1,144 | 1,266 | $56,700 | $27,599 | $27,000 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J0174 | Injection, lecanemab-irmb, 1 mg | 69,010 | $1 | $1 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 25,200 | $11 | $9 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 15,900 | $22 | $17 |
| J0897 | Injection, denosumab, 1 mg | 15,000 | $26 | $20 |
| J2182 | Injection, mepolizumab, 1 mg | 8,900 | $29 | $23 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 5,670 | $18 | $14 |
| J1756 | Injection, iron sucrose, 1 mg | 4,800 | $0 | $0 |
| J2357 | Injection, omalizumab, 5 mg | 4,665 | $38 | $30 |
| J3245 | Injection, tildrakizumab, 1 mg | 1,800 | $136 | $108 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,705 | $25 | $20 |
| 96372 | Injection of drug or substance under skin or into muscle | 795 | $13 | $10 |
| J3489 | Injection, zoledronic acid, 1 mg | 450 | $7 | $5 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Family Nurse Practitioner | 363LF0000X | ✓ | AP137008 | TX |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Family Nurse Practitioner providers in Texas
- NPI 1508783036
- NPI 1093479487
- NPI 1528524857
- NPI 1518377498
- NPI 1578926440
- NPI 1134842321
- NPI 1992053797
- NPI 1205506342
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.